ASND Quote, Financials, Valuation and Earnings

Cellectis SA has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of -142.32%. Ascendis Pharma AS's return on equity of -880.05% beat Cellectis SA's return on equity of -79.78%.

Ascendis Pharma AS has a consensus price target of $191.30, signalling upside risk potential of 42.3%. On the other hand Cellectis SA has an analysts' consensus of $6.67 which suggests that it could grow by 245.42%. Given that Cellectis SA has higher upside potential than Ascendis Pharma AS, analysts believe Cellectis SA is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.649, which suggesting that the stock is 35.145% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.082, suggesting its more volatile than the S&P 500 by 208.158%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $63.6M, which are larger than Cellectis SA quarterly revenues of $16.2M. Ascendis Pharma AS's net income of -$109.1M is lower than Cellectis SA's net income of -$23.1M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.63x versus 5.95x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of -64.14%. Ascendis Pharma AS's return on equity of -880.05% beat Evaxion Biotech AS's return on equity of --.

Ascendis Pharma AS has a consensus price target of $191.30, signalling upside risk potential of 42.3%. On the other hand Evaxion Biotech AS has an analysts' consensus of -- which suggests that it could grow by 1199.16%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.649, which suggesting that the stock is 35.145% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $63.6M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Ascendis Pharma AS's net income of -$109.1M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.63x versus 1.23x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of 38.28%. Ascendis Pharma AS's return on equity of -880.05% beat Novo Nordisk AS's return on equity of 88.95%.

Ascendis Pharma AS has a consensus price target of $191.30, signalling upside risk potential of 42.3%. On the other hand Novo Nordisk AS has an analysts' consensus of $117.14 which suggests that it could grow by 36.78%. Given that Ascendis Pharma AS has higher upside potential than Novo Nordisk AS, analysts believe Ascendis Pharma AS is more attractive than Novo Nordisk AS.

Ascendis Pharma AS has a beta of 0.649, which suggesting that the stock is 35.145% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.342%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.69% to investors and pays a quarterly dividend of $0.52 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 37.96% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ascendis Pharma AS quarterly revenues are $63.6M, which are smaller than Novo Nordisk AS quarterly revenues of $10.5B. Ascendis Pharma AS's net income of -$109.1M is lower than Novo Nordisk AS's net income of $4B. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 27.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.63x versus 9.72x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of -31.41%. Ascendis Pharma AS's return on equity of -880.05% beat Trinity Biotech PLC's return on equity of --.

Ascendis Pharma AS has a consensus price target of $191.30, signalling upside risk potential of 42.3%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 1646.42%. Given that Trinity Biotech PLC has higher upside potential than Ascendis Pharma AS, analysts believe Trinity Biotech PLC is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.649, which suggesting that the stock is 35.145% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 1.006, suggesting its more volatile than the S&P 500 by 0.60500000000001%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $63.6M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. Ascendis Pharma AS's net income of -$109.1M is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 21.63x versus 0.16x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.